NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Thursday that its fourth quarter revenues fell 18 percent compared to Q4 2014.

For the quarter ended Dec. 31, 2015, the molecular diagnostics developer reported revenues fell to $6.6 million from $8.0 million in the year-ago quarter, and missed analysts' estimate for revenues of $7.4 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.